These agents block the interaction between the PD-1 receptor on T cells and its ligands PD-L1 and PD-L2 on tumor cells, thereby enabling cytotoxic T cells to recognize and destroy tumor cells [103]. This evidence concerns the gene PDCD1LG2 and neoplasm.